Page last updated: 2024-11-04

carbinoxamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Carbinoxamine is an antihistamine that is used to treat allergies. It is available as a prescription medication and over the counter. Carbinoxamine works by blocking the action of histamine, a chemical that is released by the body in response to allergens. This helps to relieve symptoms such as sneezing, runny nose, itchy eyes, and hives. Carbinoxamine is also used to treat motion sickness and the common cold. It is available in tablet, liquid, and syrup form. Carbinoxamine is generally safe for most people. However, it can cause side effects such as drowsiness, dizziness, and dry mouth. It is important to talk to your doctor about the risks and benefits of carbinoxamine before taking it.'

carbinoxamine: Note: tradenames that start with Histex refer to more than one drug [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

carbinoxamine : An organochlorine compound that is 2-(4-chlorobenzyl)pyridine in which one of the benzylic hydrogens is substituted by 2-(dimethylamino)ethoxy group. It is an ethanolamine-type antihistamine, used as its maleate salt for treating hay fever, as well as mild cases of Parkinson's disease. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2564
CHEMBL ID864
CHEBI ID3398
SCHEMBL ID5070
MeSH IDM0045779

Synonyms (111)

Synonym
carbinoxaminum
carbinoxamina
2-[(4-chlorophenyl)(pyridin-2-yl)methoxy]-n,n-dimethylethanamine
AC-5507
BRD-A29426959-050-05-8
5-21-03-00492 (beilstein handbook reference)
unii-982a7m02h5
982a7m02h5 ,
KBIO1_000819
DIVK1C_000819
2-{[(4-chlorophenyl)(pyridin-2-yl)methyl]oxy}-n,n-dimethylethanamine
SPECTRUM_000100
BSPBIO_001933
(+-)-carbinoxamine
pyridine, 2-(p-chloro-alpha-(2-(dimethylamino)ethoxy)benzyl)-
brn 0250475
einecs 207-628-6
ethanamine, 2-((4-chlorophenyl)-2-pyridinylmethoxy)-n,n-dimethyl-
n,n-dimethyl-2-(p-chloro-alpha-(2-pyridyl)benzyloxy)ethylamine
carbinoxamine [inn:ban]
carbinoxamina [inn-spanish]
carbinoxaminum [inn-latin]
OPREA1_764868
PRESTWICK3_000801
carbinoxamine (inn)
D07617
BPBIO1_000729
IDI1_000819
BSPBIO_000661
PRESTWICK2_000801
AB00053430
carbinoxamine
486-16-8
C06871
allergefon
ethanamine, 2-[(4-chlorophenyl)-2-pyridinylmethoxy]-n,n-dimethyl-
{2-[(4-chlorophenyl)-2-pyridylmethoxy]ethyl}dimethylamine
mcn-r 73z
paracarbinoxamine
2-[(4-chlorophenyl)-(2-pyridyl)methoxy]-n,n-dimethyl-ethanamine
(+/-)-carbinoxamine
2-(p-chloro-alpha-(2-(dimethylamino)ethoxy)benzyl)pyridine
DB00748
{2-[(4-chloro-phenyl)-pyridin-2-yl-methoxy]-ethyl}-dimethyl-amine
NCGC00166141-01
carbinoxamine base
KBIOGR_000728
KBIO2_000520
KBIO3_001153
KBIO2_003088
KBIO2_005656
KBIOSS_000520
PRESTWICK0_000801
NINDS_000819
PRESTWICK1_000801
SPBIO_002582
SPECTRUM4_000264
SPBIO_000993
SPECTRUM3_000327
SPECTRUM2_001127
SPECTRUM5_000700
NCGC00166141-02
NCGC00166141-03
palgic
CHEMBL864
chebi:3398 ,
AKOS003334261
L000924
FT-0652011
2-[(4-chlorophenyl)-pyridin-2-ylmethoxy]-n,n-dimethylethanamine
nsc_2564
bdbm81464
cas_486-16-8
2-[(4-chlorophenyl)-(2-pyridyl)methoxy]ethyl-dimethyl-amine;fumaric acid
NCGC00166141-04
2-((4-chlorophenyl)(pyridin-2-yl)methoxy)-n,n-dimethylethanamine
A827570
paracarinoxamine
carbinoxamine-d6 maleate salt
{2-[(4-chlorophenyl)(pyridin-2-yl)methoxy]ethyl}dimethylamine
gtpl7139
2-(p-chloro-.alpha.-(2-(dimethylamino)ethoxy)benzyl)pyridine
carbinoxamine [mi]
carbinoxamine [inn]
carbinoxamine [who-dd]
carbinoxamine [vandf]
SCHEMBL5070
(.+/-.)-carbinoxamine
carbinoxamine maleate (salt/mix)
pyridine, 2-[p-chloro-.alpha.-[2-(dimethylamino)ethoxy]benzyl]-
OJFSXZCBGQGRNV-UHFFFAOYSA-N
clistin (salt/mix)
ziriton (salt/mix)
rondec (salt/mix)
AKOS016843886
AB00053430_12
DTXSID4022737 ,
SBI-0051304.P003
Q3728177
BRD-A29426959-050-07-4
carbinoxamine; mcn-r 73z; paracarbinoxamine; paracarinoxamine
2-[(4-chlorophenyl)-pyridin-2-yl-methoxy]-n,n-dimethyl-ethanamine
()-carbinoxamine
SB82406
EN300-755282
(2-((4-chloro-phenyl)-pyridin-2-yl-methoxy)-ethyl)-dimethyl-amine
dtxcid302737
carbinoxamina (inn-spanish)
carbinoxaminum (inn-latin)
carbinoxamin
r06aa08

Research Excerpts

Overview

Carbinoxamine maleate is an antihistamine drug with mild sedation effects. It is used to treat seasonal and perennial allergic rhinitis clinically.

ExcerptReferenceRelevance
"Carbinoxamine maleate is an antihistamine drug with mild sedation effects, which is used to treat seasonal and perennial allergic rhinitis clinically. "( Development and full validation of a liquid chromatography-tandem mass spectrometry method for determination of carbinoxamine in beagle plasma and its application to a pharmacokinetic study.
Bi, K; Li, P; Li, Q; Liu, J; Liu, R; Xiao, J, 2018
)
2.13

Pharmacokinetics

The pharmacokinetic characteristics of carbinoxamine were subsequently evaluated in beagles. This method can be used suitably for pharmacokinetics studies and in therapeutic drug monitoring.

ExcerptReferenceRelevance
" The pharmacokinetic characteristics of carbinoxamine were subsequently evaluated in beagles."( Development and full validation of a liquid chromatography-tandem mass spectrometry method for determination of carbinoxamine in beagle plasma and its application to a pharmacokinetic study.
Bi, K; Li, P; Li, Q; Liu, J; Liu, R; Xiao, J, 2018
)
0.96
" This method can be used suitably for pharmacokinetic studies and in therapeutic drug monitoring in patients treated with carbinoxamine."( Simple HPLC Method for Quantitative Determination of Carbinoxamine in Human Plasma: Application in Pharmacokinetic Studies and Therapeutic Drug Monitoring.
El-Masry, SM; El-Morsi, RM, 2019
)
0.97

Dosage Studied

ExcerptRelevanceReference
" A simulation of the plasma levels during repeated administration indicated that dosing with the retard suspension at 12-h intervals should yield the same steady-state plasma levels as a 5 times daily administration of a divided dose of the aqueous solution, for both drugs."( Relative bioavailability of carbinoxamine and phenylpropanolamine from a retard suspension after single dose administration in healthy subjects.
Allemon, AM; Deroubaix, X; Laufen, H; Lebacq, E; Stockis, A, 1992
)
0.58
" The side-effects observed were mild in nature and did not require reduction in dosage or withdrawal of the drug in any of the patients."( A comparative randomized double-blind clinical trial of hexapneumine and clistine as antitussive agents.
Chakrabarti, A; Jindal, SK; Malik, SK; Pandhi, P; Sharma, PL, 1987
)
0.27
"An isocratic, reversed-phase liquid chromatographic (LC) method was developed for simultaneous determination of pseudoephedrine hydrochloride (I) and carbinoxamine maleate (II) in a pharmaceutical dosage form."( Determination of pseudoephedrine hydrochloride and carbinoxamine maleate in combination drug formulation by liquid chromatography.
Mansour, AM,
)
0.58
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
H1-receptor antagonistH1-receptor antagonists are the drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine.
anti-allergic agentA drug used to treat allergic reactions.
muscarinic antagonistA drug that binds to but does not activate muscarinic cholinergic receptors, thereby blocking the actions of endogenous acetylcholine or exogenous agonists.
antiparkinson drugA drug used in the treatment of Parkinson's disease.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
monochlorobenzenesAny member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Carbinoxamine H1-Antihistamine Action87

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
lamin isoform A-delta10Homo sapiens (human)Potency35.48130.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
Voltage-dependent L-type calcium channel subunit alpha-1CRattus norvegicus (Norway rat)Ki1.08000.00080.57965.4000AID364004
Voltage-dependent L-type calcium channel subunit alpha-1DRattus norvegicus (Norway rat)Ki1.08000.00080.74105.4000AID364004
Voltage-dependent L-type calcium channel subunit alpha-1SRattus norvegicus (Norway rat)Ki1.08000.00080.66735.4000AID364004
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (33)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID363997Negative inotropic activity in guinea pig left atrium assessed as decrease in atrial tension relative to control2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of novel and cardioselective diltiazem-like calcium channel blockers via virtual screening.
AID363988Negative inotropic activity in guinea pig left atrium assessed as decrease in atrial tension at 100 uM relative to control2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of novel and cardioselective diltiazem-like calcium channel blockers via virtual screening.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID363993Negative chronotropic activity in guinea pig spontaneously beating right atrium assessed as decrease in atrial rate at 100 uM relative to control2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of novel and cardioselective diltiazem-like calcium channel blockers via virtual screening.
AID364004Displacement of [3H]diltiazem from L-type calcium channel in Sprague-Dawley rat cardiac myocytes2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of novel and cardioselective diltiazem-like calcium channel blockers via virtual screening.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1774079Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 10 uM incubated for 1 week by absorbance method2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID364001Vasorelaxant activity in K+-depolarized guinea pig ileum longitudinal smooth muscle assessed as inhibition of calcium-induced contraction at 50 uM2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of novel and cardioselective diltiazem-like calcium channel blockers via virtual screening.
AID364003Vasorelaxant activity in K+-depolarized guinea pig ileum longitudinal smooth muscle assessed as inhibition of calcium-induced contraction2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of novel and cardioselective diltiazem-like calcium channel blockers via virtual screening.
AID363998Vasorelaxant activity in K+-depolarized guinea pig aorta assessed as inhibition of calcium-induced contraction at 100 uM2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of novel and cardioselective diltiazem-like calcium channel blockers via virtual screening.
AID227718Binding energy by using the equation deltaG obsd = -RT ln KD1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Functional group contributions to drug-receptor interactions.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625278FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of no concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1774078Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 4 uM incubated for 1 week by absorbance method2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1774076Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli at 400 uM incubated for 1 hr in presence of 75 uM ANS by fluorescence method (Rvb = 91 +/- 0.92%)2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1774075Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli assessed as ANS saturation ratio at 400 uM incubated for 1 hr in presence of 7.5 uM ANS by fluorescence method (Rvb = 56 +/- 2.3%)2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (38)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (26.32)18.7374
1990's3 (7.89)18.2507
2000's6 (15.79)29.6817
2010's15 (39.47)24.3611
2020's4 (10.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 62.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index62.23 (24.57)
Research Supply Index3.85 (2.92)
Research Growth Index4.91 (4.65)
Search Engine Demand Index100.90 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (62.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (12.20%)5.53%
Reviews1 (2.44%)6.00%
Case Studies2 (4.88%)4.05%
Observational0 (0.00%)0.25%
Other33 (80.49%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]